NASDAQ:EVO Evotec Q3 2026 Earnings Date & Estimates $1.53 -0.04 (-2.55%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.53 0.00 (0.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Evotec is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 6:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call6:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Evotec in Q3 2026Evotec is expected to post earnings of -$0.3087 per share on revenue of $167.20 million.Consensus EstimatesConsensus EPS-$0.3087Expected Revenue$167.20 millionRecent Track RecordLast ReportedQ4 2025Last Quarter EPS$0.05Last Quarter Revenue$297.02 millionPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ4 2025 Earnings ReportQ2 2021 Earnings ReportQ1 2021 Earnings Report Evotec Q3 2026 Earnings FAQ When does Evotec report Q3 2026 earnings? Evotec (NASDAQ:EVO) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Evotec's Q3 2026 earnings call? Evotec's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 6:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Evotec? Analysts expect Evotec to post earnings of -$0.3087 per share for Q3 2026. How much revenue is Evotec expected to report? The consensus revenue estimate for Evotec is $167.20 million for Q3 2026. Evotec Earnings HeadlinesBiotech rally 2027: Patents, blockbusters and biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo NordiskOctober 9 at 3:54 PM | msn.comEvotec, DroneShield and Power Metallic Mines: Turnaround opportunities, defence boom and commodities hidden gemOctober 2, 2026 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 11 at 1:00 AM | Weiss Ratings (Ad)Evotec Chief Scientific Officer to DepartSeptember 29, 2026 | marketscreener.comMEvotec Announces Chief Scientific Officer TransitionSeptember 29, 2026 | prnewswire.comBerenberg Bank Sticks to Their Hold Rating for Evotec (0IRF)September 27, 2026 | theglobeandmail.comSee More Evotec Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evotec? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evotec and other key companies, straight to your email. Email Address About EvotecEvotec (NASDAQ:EVO) SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies. Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services. Evotec also operates technology platforms for areas such as proteomics, data-driven drug discovery, induced pluripotent stem cells and biologics. Through its Just – Evotec Biologics business, the company develops biologic medicines and related manufacturing technologies. Evotec serves partners internationally through research and development sites in Europe and the United States. Its collaborations span therapeutic areas including neuroscience, oncology, metabolic disease, infectious disease and immunology. The company is led by Chief Executive Officer Christian Wojczewski, who joined Evotec’s executive leadership in 2024.View Evotec ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
